USFDA Approval for Alembic Pharmaceuticals’ Fenofibrate Tablets USP, 48 mg and 145 mg.
Posted on August 13, 2019
Alembic Pharmaceuticals Limited today announced that the Company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fenofibrate Tablets USP, 48 mg and 145 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Tricor Tablets, 48 mg and 145 mg, of AbbVie Inc. (AbbVie). Fenofibrate Tablets, USP are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDLC) in adult patients with primary hypercholesterolernla or mixed dyslipidemia. It is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dl) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.
Fenofibrate Tablets USP, 48 mg and 145 mg have an estimated market size of US$ 94 million for twelve months ending December 201-8 according to IQVIA.
Alembic now has a total of 102 ANDA approvals (90 final approvals and 12 tentative approvals) from USFDA.
Related Topics and Keywords
Subscribe to our FREE newsletter